Pioneering ImmunoViroTherapy for Cancer

Healthcare Professional
Trusted Provider

Advancing ImmunoViroTherapy From India, For The World.

Founded in Bangalore, Neovira Therapeutics is pioneering next-generation oncolytic viruses and immune cell-based therapy that selectively target and destroy cancer cells while sparing healthy tissue. By integrating advanced virology, immunology, and scalable manufacturing, we are building accessible, globally relevant therapies that redefine how cancer is treated.

About Us

Why We Are

At Neovira, we harness the power of oncolytic viruses, engineered to replicate within and destroy tumor cells while sparing healthy tissue. This dual action not only targets cancer cells directly but also stimulate the immune system for durable response.

Modern hospital facility
Doctor consultation
Medical procedure
Lead Candidate Efficacy – Demonstrated strong tumor reduction in glioblastoma (GBM) and gastrointestinal (GI)- related cell cultures and animal models.
Manufacturing Progress – GMP-grade production is currently underway.
Clinical Development – Preparing for upcoming Phase I/II clinical trials.
Pipeline Strategy – Initial focus on GBM, GI with plans to expand into other brain and solid tumors with high disease burden.